{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:47:52Z","timestamp":1792759672781,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49617-6","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T05:53:24Z","timestamp":1777182804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Qi-lin","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"key":"49617_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.22.02754","volume":"42","author":"M His","year":"2024","unstructured":"His, M., Gunter, M. J., Keski-Rahkonen, P. & Rinaldi, S. Application of metabolomics to epidemiologic studies of breast cancer: New perspectives for etiology and prevention. JCO. 42, 103\u2013115 (2024).","journal-title":"JCO"},{"key":"49617_CR2","doi-asserted-by":"publisher","first-page":"102339","DOI":"10.1016\/j.ctrv.2022.102339","volume":"104","author":"D Trapani","year":"2022","unstructured":"Trapani, D. et al. Global challenges and policy solutions in breast cancer control. Cancer Treat. Rev. 104, 102339 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"49617_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","volume":"23","author":"M Will","year":"2023","unstructured":"Will, M., Liang, J., Metcalfe, C. & Chandarlapaty, S. Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat. Rev. Cancer. 23, 673\u2013685 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"49617_CR4","unstructured":"Li, J. J. & Tse, G. M. Marker assessments in ER positive breast cancers-old markers, new applications?"},{"key":"49617_CR5","doi-asserted-by":"publisher","first-page":"154298","DOI":"10.1016\/j.prp.2022.154298","volume":"241","author":"MR Castellanos","year":"2023","unstructured":"Castellanos, M. R. et al. Expression patterns and clinical significance of estrogen receptor in non-small cell lung cancer. Pathol. - Res. Pract. 241, 154298 (2023).","journal-title":"Pathol. - Res. Pract."},{"key":"49617_CR6","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s13346-023-01299-7","volume":"13","author":"M Aalhate","year":"2023","unstructured":"Aalhate, M., Mahajan, S., Singh, H., Guru, S. K. & Singh, P. K. Nanomedicine in therapeutic warfront against estrogen receptor\u2013positive breast cancer. Drug Deliv. Transl. Res. 13, 1621\u20131653 (2023).","journal-title":"Drug Deliv. Transl. Res."},{"key":"49617_CR7","doi-asserted-by":"publisher","first-page":"1015388","DOI":"10.3389\/fendo.2022.1015388","volume":"13","author":"T Reinert","year":"2022","unstructured":"Reinert, T. et al. Clinical implication of low estrogen receptor (ER-low) expression in breast cancer. Front. Endocrinol. 13, 1015388 (2022).","journal-title":"Front. Endocrinol."},{"key":"49617_CR8","doi-asserted-by":"publisher","first-page":"102952","DOI":"10.1016\/j.redox.2023.102952","volume":"68","author":"Z Xu","year":"2023","unstructured":"Xu, Z. et al. RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer. Redox Biol. 68, 102952 (2023).","journal-title":"Redox Biol."},{"key":"49617_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker, A. B., Sudhan, D. R. & Arteaga, C. L. Overcoming endocrine resistance in breast cancer. Cancer Cell. 37, 496\u2013513 (2020).","journal-title":"Cancer Cell."},{"key":"49617_CR10","doi-asserted-by":"publisher","first-page":"216968","DOI":"10.1016\/j.canlet.2024.216968","volume":"593","author":"S Belli","year":"2024","unstructured":"Belli, S. et al. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4\/6 inhibitors in ER+ breast cancer. Cancer Lett. 593, 216968 (2024).","journal-title":"Cancer Lett."},{"key":"49617_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3892\/or.2022.8320","volume":"47","author":"T Takeda","year":"2022","unstructured":"Takeda, T. et al. EGFR inhibition reverses epithelial\u2013mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells. Oncol. Rep. 47, 109 (2022).","journal-title":"Oncol. Rep."},{"key":"49617_CR12","doi-asserted-by":"publisher","first-page":"C708","DOI":"10.1152\/ajpcell.00199.2023","volume":"325","author":"KE Siatis","year":"2023","unstructured":"Siatis, K. E. et al. Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway. Am. J. Physiol.-Cell Physiol. 325, C708\u2013C720 (2023).","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"49617_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41419-021-03787-5","volume":"12","author":"T Itoh","year":"2021","unstructured":"Itoh, T. et al. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. Cell. Death Dis. 12, 520 (2021).","journal-title":"Cell. Death Dis."},{"key":"49617_CR14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1186\/s12885-021-08641-7","volume":"21","author":"SY Moon","year":"2021","unstructured":"Moon, S. Y. et al. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells. BMC Cancer. 21, 931 (2021).","journal-title":"BMC Cancer"},{"key":"49617_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/med.21739","volume":"41","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P\u2010glycoprotein (P\u2010gp). Med. Res. Rev. 41, 525\u2013555 (2021).","journal-title":"Med. Res. Rev."},{"key":"49617_CR16","doi-asserted-by":"publisher","first-page":"100754","DOI":"10.1016\/j.drup.2021.100754","volume":"55","author":"T Das","year":"2021","unstructured":"Das, T. et al. Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist. Updates. 55, 100754 (2021).","journal-title":"Drug Resist. Updates"},{"key":"49617_CR17","doi-asserted-by":"publisher","first-page":"102494","DOI":"10.1016\/j.nano.2021.102494","volume":"40","author":"J Halder","year":"2022","unstructured":"Halder, J., Pradhan, D., Kar, B., Ghosh, G. & Rath, G. Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer. Nanomed. Nanotechnol. Biol. Med. 40, 102494 (2022).","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"49617_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/med.21739","volume":"41","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P\u2010glycoprotein (P\u2010gp). Med. Res. Rev. 41, 525\u2013555 (2021).","journal-title":"Med. Res. Rev."},{"key":"49617_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/FPC.0000000000000486","volume":"33","author":"DN Keller","year":"2023","unstructured":"Keller, D. N., Medwid, S. J., Ross, C. D., Wigle, T. J. & Kim, R. B. Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. Pharmacogenet. Genom.. 33, 10\u201318 (2023).","journal-title":"Pharmacogenet. Genom."},{"key":"49617_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12885-022-10474-x","volume":"23","author":"R Bakadlag","year":"2023","unstructured":"Bakadlag, R., Limniatis, G., Georges, G. & Georges, E. The anti-estrogen receptor drug, tamoxifen, is selectively Lethal to P-glycoprotein-expressing Multidrug resistant tumor cells. BMC Cancer. 23, 24 (2023).","journal-title":"BMC Cancer"},{"key":"49617_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/pharmaceutics15010067","volume":"15","author":"DP Zlotos","year":"2022","unstructured":"Zlotos, D. P., Kronenberger, T. & Laufer, S. A. Anticancer drug conjugates incorporating estrogen receptor ligands. Pharmaceutics 15, 67 (2022).","journal-title":"Pharmaceutics"},{"key":"49617_CR22","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jamasurg.2023.5113","volume":"158","author":"SA Khan","year":"2023","unstructured":"Khan, S. A. et al. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial. JAMA Surg. 158, 1265 (2023).","journal-title":"JAMA Surg."},{"key":"49617_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.21873\/cgp.20403","volume":"20","author":"G Bauerschmitz","year":"2023","unstructured":"Bauerschmitz, G., H\u00fcchel, S., Gallwas, J. & Gr\u00fcndker, C. Inhibition of increased invasiveness of breast cancer cells with acquired tamoxifen resistance by suppression of CYR61. Cancer Genom. Proteom. 20, 531\u2013538 (2023).","journal-title":"Cancer Genomics Proteom."},{"key":"49617_CR24","doi-asserted-by":"publisher","first-page":"592912","DOI":"10.3389\/fphar.2020.592912","volume":"11","author":"J Yao","year":"2020","unstructured":"Yao, J., Deng, K., Huang, J., Zeng, R. & Zuo, J. Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer. Front. Pharmacol. 11, 592912 (2020).","journal-title":"Front. Pharmacol."},{"key":"49617_CR25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/cpt.3380","volume":"116","author":"S Medwid","year":"2024","unstructured":"Medwid, S. et al. Solanidine metabolites as diet-derived biomarkers of CYP2D6\u2010mediated tamoxifen metabolism in breast cancer patients. Clin. Pharma Ther. 116, 1269\u20131277 (2024).","journal-title":"Clin. Pharma Ther."},{"key":"49617_CR26","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/cpt.3238","volume":"116","author":"AM Mc Laughlin","year":"2024","unstructured":"Mc Laughlin, A. M. et al. Nonlinear mixed-effects model of Z\u2010endoxifen concentrations in tamoxifen\u2010treated patients from the CEPAM cohort. Clin. Pharma Ther. 116, 690\u2013702 (2024).","journal-title":"Clin. Pharma Ther."},{"key":"49617_CR27","doi-asserted-by":"publisher","first-page":"738222","DOI":"10.3389\/fonc.2021.738222","volume":"11","author":"H Pang","year":"2021","unstructured":"Pang, H. et al. Evaluating the risk of breast cancer recurrence and metastasis after adjuvant tamoxifen therapy by integrating polymorphisms in cytochrome P450 genes and clinicopathological characteristics. Front. Oncol. 11, 738222 (2021).","journal-title":"Front. Oncol."},{"key":"49617_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41419-023-06181-5","volume":"14","author":"C Jiang","year":"2023","unstructured":"Jiang, C. et al. Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer. Cell. Death Dis. 14, 653 (2023).","journal-title":"Cell. Death Dis."},{"key":"49617_CR29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.tem.2022.02.002","volume":"33","author":"X Weng","year":"2022","unstructured":"Weng, X. et al. The membrane receptor CD44: Novel insights into metabolism. Trends Endocrinol. Metab. 33, 318\u2013332 (2022).","journal-title":"Trends Endocrinol. Metab"},{"key":"49617_CR30","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1021\/acsanm.5c05586","volume":"9","author":"Y Zeng","year":"2026","unstructured":"Zeng, Y. et al. Induction of ferroptosis by dual-targeting pH-responsive nanomicelles in the treatment of tamoxifen-resistant breast cancer. ACS Appl. Nano Mater. 9, 1696\u20131709 (2026).","journal-title":"ACS Appl. Nano Mater."},{"key":"49617_CR31","doi-asserted-by":"crossref","unstructured":"Tinghe, Y. et al. Determining the interaction in a drug combination using the dose-based or effect-based method. Curr. Neuropharmacol. 23, 1260\u20131263 (2025).","DOI":"10.2174\/011570159X347472250130111339"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49617-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T23:08:02Z","timestamp":1782083282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49617-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49617"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49617-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,26]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal protocols were approved by the Research Ethics Committee of Bengbu Medical University (2023 No. 281).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the final version of the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19243"}}